The newly established institute is equipped with advanced infrastructure designed to integrate multiple specialties under one roof
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
The new outpatient-focused clinic is designed to address voice, airway and swallowing disorders through advanced diagnostics
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Subscribe To Our Newsletter & Stay Updated
